Butyric Acid Ameliorates Myocardial Fibrosis by Regulating M1/M2 Polarization of Macrophages and Promoting Recovery of Mitochondrial Function

Xiaogang Li, Ruixuan Li, Nana You, Xiexiong Zhao, Jiaying Li, Weihong JiangFrontiers in Nutrition 2022 · DOI

TL;DR

This study investigates how butyric acid, a gut microbiota metabolite, can alleviate myocardial fibrosis (MF) in rats. The research reveals that butyric acid helps by shifting the balance of immune cells (macrophages) towards an anti-inflammatory state and improving the function of mitochondria, offering a potential therapeutic avenue for heart disease.

What Problem Does This Paper Address?

Myocardial fibrosis (MF) is a significant pathological process in advanced cardiovascular diseases, characterized by the excessive deposition of extracellular matrix proteins in the heart. This scarring impairs heart function and can lead to severe cardiac dysfunction and even death. Current treatments for MF are limited, highlighting the need for novel therapeutic strategies. Emerging research points to the "gut-heart axis," suggesting that the gut microbiota and its metabolites play a crucial role in cardiovascular health. Specifically, butyric acid, a short-chain fatty acid (SCFA) produced by gut bacteria, has shown promise in various health contexts. However, its precise mechanism in mitigating myocardial fibrosis, particularly its impact on immune cell polarization and mitochondrial function, remained unclear. This paper aims to elucidate these mechanisms.

Methods

The researchers employed a multi-pronged approach:

  • Animal Model: A rat model of myocardial fibrosis was established using transverse aortic constriction (TAC).
  • Gut Microbiota Analysis: 16S rRNA sequencing was used to characterize the gut microbial communities in both healthy (Sham) and fibrotic (MF) rats.
  • Metabolite Measurement: High-Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS) was used to quantify butyric acid levels in plasma and feces. Lipopolysaccharide (LPS) levels were also measured.
  • In Vitro Macrophage Studies: Rat macrophages (RMa-bm) were stimulated to differentiate into M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotypes using LPS and IL-4, respectively. The effect of butyric acid on this polarization and on mitochondrial function (assessed by JC-1 staining for mitochondrial membrane potential and ATP content) was then evaluated.
  • In Vitro Fibroblast Studies: Rat myocardial fibroblasts were co-cultured with macrophages to assess the impact of butyric acid on fibroblast proliferation, senescence, and apoptosis. Gene expression analysis (qRT-PCR) was performed for apoptosis and senescence-related proteins, as well as inflammatory cytokines.
  • In Vivo Treatment: Rats with established MF were fed a diet supplemented with butyric acid to evaluate its therapeutic effects on cardiac and gut tissue morphology, as well as inflammatory markers.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from animal models and cell cultures.

Key Insights and Ideas

  • Gut Dysbiosis in MF: The study identified specific changes in the gut microbiota of MF rats, with an increased abundance of Desulfovibrionaceae and Helicobacteraceae. This suggests a link between gut health and cardiac fibrosis.
  • Butyric Acid Deficiency in MF: MF rats showed decreased levels of butyric acid in both plasma and feces, and importantly, butyric acid levels were negatively correlated with the abundance of the pro-inflammatory gut bacteria identified. This strongly suggests that butyric acid deficiency may contribute to MF.
  • Butyric Acid Repolarizes Macrophages: A key finding is that butyric acid effectively shifts macrophages from a pro-inflammatory M1 state towards an anti-inflammatory M2 state. This is crucial because M1 macrophages are implicated in promoting fibrosis, while M2 macrophages are involved in tissue repair.
  • Mitochondrial Function Restoration: Butyric acid treatment improved mitochondrial membrane potential and ATP production in macrophages, suggesting it can restore mitochondrial health, which is vital for cellular energy production and overall function, especially in the energy-demanding heart.
  • Inhibition of Fibroblast Activity: In co-culture experiments, butyric acid reduced the proliferation of myocardial fibroblasts and increased their senescence and apoptosis. This indicates that butyric acid directly counteracts the cells responsible for excessive collagen deposition in MF.
  • In Vivo Therapeutic Effect: Supplementation with butyric acid in MF rats led to improvements in cardiac and gut tissue morphology, reduced inflammation, and alleviated symptoms, reinforcing the in vitro findings.

Key Results

  • MF Model Validation: Echocardiography confirmed reduced ejection fraction (EF) and fractional shortening (FS) in MF rats, while Masson staining showed significant collagen deposition and fibrosis.
  • Gut Microbiota Changes: PCA analysis revealed distinct microbial communities between Sham and MF groups. Desulfovibrionaceae and Helicobacteraceae were significantly increased in the MF group.
  • Butyric Acid and LPS Levels: MF rats had increased plasma LPS and decreased butyric acid levels. Fecal and serum butyric acid content was also lower in MF rats.
  • Macrophage Polarization: Butyrate treatment significantly reduced M1 markers (CD86, CD80, CD64, CD16/32, TNF-α) and increased M2 markers (CD163, CD206, IL-10) in macrophages.
  • Mitochondrial Function: Butyrate improved mitochondrial membrane potential and ATP content in both LPS- and IL-4-stimulated macrophages.
  • Fibroblast Activity: Butyrate decreased myocardial fibroblast proliferation and increased senescence and apoptosis. Gene expression analysis showed altered levels of apoptosis and inflammatory markers consistent with reduced fibroblast activity.
  • In Vivo Improvement: HE staining of heart and gut tissues in butyrate-treated MF rats showed improved morphology, reduced inflammatory infiltration, and less disordered tissue arrangement compared to untreated MF rats. Plasma levels of pro-inflammatory cytokines (IL-6, TNF-α, IL-12) and LPS were also reduced by butyrate treatment.

Limitations and Future Work

  • Gut Microbiota Changes Post-Treatment: The study acknowledges a limitation in not examining the changes in gut microbiota composition after butyrate supplementation in the MF rats. Future work should include 16S rRNA sequencing of the Sham, MF, and Butyrate groups to fully understand how butyrate influences the gut microbiome.
  • Mechanism of Mitochondrial Protection: While the study shows butyrate promotes mitochondrial function recovery, the exact molecular mechanisms underlying this effect, particularly in relation to macrophage polarization, warrant further investigation.
  • Clinical Translation: The findings provide a strong basis for further research into the therapeutic potential of butyric acid or strategies to increase its production for the treatment of myocardial fibrosis in humans.

Summary updated

Abstract

Butyric acid ameliorated MF by regulating M1/M2 polarization of macrophages and promoting recovery of mitochondrial function.
BibTeX
@inproceedings{li2022butyric,
  author = {Xiaogang Li and Ruixuan Li and Nana You and Xiexiong Zhao and Jiaying Li and Weihong Jiang},
  title = {{Butyric Acid Ameliorates Myocardial Fibrosis by Regulating M1/M2 Polarization of Macrophages and Promoting Recovery of Mitochondrial Function}},
  booktitle = {Frontiers in Nutrition},
  year = {2022},
  doi = {10.3389/fnut.2022.875473},
}
Figure